AUS
NZ
UK
CA
USA
IND
Dimerix Limited (ASX:DXB), a clinical-stage biopharmaceutical firm specializing in kidney disease therapies, has acquired DMX-652 from Mission Therapeutics Limited. This Phase 2-ready candidate targets acute kidney injury (AKI) and includes an open US Investigational New Drug (IND) application along with FDA approval to proceed with Phase 2 clinical trials. This acquisition positions Dimerix to address a critical unmet medical need in a global market projected to reach US$3.5 billion by 2026. The move strategically broadens Dimerix's renal pipeline alongside its lead Phase 3 asset DMX-200 for focal segmental glomerulosclerosis (FSGS).
Key Points
- Dimerix Limited (ASX:DXB) has secured DMX-652, a Phase 2-ready therapeutic candidate for acute kidney injury, from Mission Therapeutics Limited
- DMX-652 acts as a selective USP30 inhibitor aimed at preventing acute kidney injury by preserving renal function through mitochondrial quality control
- A completed Phase 1 trial with 85 healthy volunteers showed DMX-652 was well tolerated at single doses up to 200mg daily and multiple doses up to 100mg daily over 14 days, with no serious adverse events reported
- The global acute kidney injury treatment market is estimated at US$3.5 billion in 2026, with an addressable US patient population of approximately 100,000 to 133,000 annually
- The acquisition includes composition of matter patent, open IND, FDA-approved Phase 2 trial protocol, and manufacturing methodology; upfront payment and Phase 2 trial funding are fully secured
- Investors should track the Phase 2 clinical trial progress in cardiac surgery-associated AKI and ongoing development of the complementary DMX-200 Phase 3 FSGS program
Dimerix Strategically Enters Acute Kidney Injury Therapeutics Market
Dimerix Limited has strategically expanded its clinical pipeline by acquiring DMX-652, extending its focus beyond rare glomerular kidney diseases into acute kidney injury. This acquisition significantly enhances the company’s renal disease portfolio, enabling it to address acute kidney injury while leveraging its existing expertise in kidney disease treatment development. The addition of DMX-652 allows Dimerix to capitalize on its global network and operational infrastructure without building a new therapeutic program from scratch.
The timing coincides with the completion of Dimerix’s Phase 3 ACTION3 trial for its lead asset DMX-200 in FSGS, underscoring the company’s confidence in advancing multiple clinical programs simultaneously. By incorporating a Phase 2-ready asset, Dimerix positions itself as a comprehensive kidney disease therapeutics player, targeting both acute injury and chronic disease mechanisms. This strategic focus on high-value, differentiated indications reflects a disciplined pipeline development approach in rare kidney diseases.
DMX-652: Mechanism of Action and Phase 1 Clinical Data
DMX-652 selectively inhibits USP30, a mitochondrial enzyme that delays removal of damaged mitochondria from cells. Formulated as an oral once-daily capsule, DMX-652 supports mitochondrial quality control in injured kidney cells, a mechanism relevant to AKI caused by ischemia, toxins, or sepsis. This novel approach positions DMX-652 as a first-in-class therapeutic with no known clinical competitors targeting similar mechanisms for AKI.
The Phase 1 trial involving 85 healthy participants confirmed DMX-652’s safety and tolerability, with single doses up to 200mg and multiple doses up to 100mg daily over 14 days showing no serious adverse events. Pharmacokinetic data supported the oral once-daily dosing regimen. This strong safety profile underpins progression into the FDA-approved Phase 2 clinical trial.
Market Potential and Unmet Need in Acute Kidney Injury
Acute kidney injury is a widespread, severe condition marked by rapid kidney function decline and high morbidity and mortality. The US addressable patient population is estimated between 100,000 and 133,000 annually, potentially qualifying as an orphan indication. The global market for AKI treatments is projected to reach US$3.5 billion in 2026 and is expected to grow to approximately US$7.5 billion over the next decade, presenting a substantial commercial opportunity.
AKI often occurs in high-risk settings such as cardiac surgery and sepsis. Despite advances in care, no approved therapies currently exist to prevent or treat AKI, highlighting a significant treatment gap. Cardiac surgery-associated AKI, caused by ischemia-reperfusion injury during on-pump procedures, aligns well with DMX-652’s mitochondrial-targeted mechanism, making it an ideal initial clinical target.
Focus on Cardiac Surgery-Associated Acute Kidney Injury for Phase 2 Trial
The Phase 2 trial will target cardiac surgery-associated AKI (CS-AKI), a predictable complication from cardiopulmonary bypass and valve surgeries. This multicenter study will evaluate DMX-652’s ability to prevent kidney injury and preserve renal function in cardiac surgery patients. The indication was chosen due to the predictable nature of CS-AKI, a large at-risk population, and the lack of approved preventive therapies.
CS-AKI results from ischemia followed by reperfusion during surgery, a pathophysiology directly addressed by DMX-652’s mechanism supporting mitochondrial quality control. AKI following cardiac surgery contributes to increased morbidity, mortality, longer hospital stays, and higher risk of chronic kidney and cardiovascular complications. Advancing DMX-652 into Phase 2 for CS-AKI targets a major clinical challenge affecting many patients.
Comprehensive Intellectual Property and Manufacturing Rights Included
Dimerix’s acquisition from Mission Therapeutics includes the composition of matter patent protecting DMX-652’s chemical entity, granting exclusive development and commercialization rights. The deal also transfers an open US IND application and FDA-approved Phase 2 trial protocol, enabling immediate clinical progression without regulatory delays.
Manufacturing capabilities and methodology have been included, along with sufficient GMP-compliant drug inventory to support the Phase 2 trial. This thorough transfer of IP, regulatory approvals, and manufacturing assets allows Dimerix to efficiently advance DMX-652 without investing in early-stage development or regulatory processes, accelerating clinical timelines.
Acquisition Funding and Financial Strategy
Dimerix structured the DMX-652 acquisition to minimize upfront capital needs and preserve financial flexibility. The upfront payment and Phase 2 trial funding are fully secured from existing resources, as announced on 17 July 2026. This funding was arranged alongside the completion of the ACTION3 Phase 3 trial for DMX-200, reducing dilution risk for current shareholders.
The company is also exploring non-dilutive funding options, including milestone-based payments, regulatory and commercial milestones, and potential partnerships or licensing agreements with larger pharmaceutical firms. These strategies aim to support DMX-652’s development through Phase 2 and beyond while limiting equity dilution.
Synergy With DMX-200 Phase 3 Program and Renal Portfolio
DMX-652 complements Dimerix’s lead asset DMX-200, currently in a fully recruited Phase 3 pivotal trial for FSGS, a rare kidney disease. While DMX-200 targets chronic glomerular disease, DMX-652 addresses acute kidney injury via mitochondrial quality control. This portfolio diversification enables Dimerix to serve multiple kidney disease populations and capture value across acute and chronic segments.
The acquisition leverages Dimerix’s expertise in kidney disease biology, clinical trial management, and global relationships with renal specialists and treatment centers. Integrating DMX-652 expands Dimerix’s renal franchise beyond glomerular disease into acute kidney injury, reflecting a disciplined growth strategy focused on high-value, unmet medical needs with differentiated mechanisms aligned to the company’s core competencies.
Potential Expansion of DMX-652 Into Additional Indications
Although the initial Phase 2 trial targets cardiac surgery-associated AKI, DMX-652’s selective USP30 inhibition mechanism may allow expansion into other renal and non-renal indications. Mitochondrial dysfunction is implicated in chronic kidney disease progression, diabetic kidney disease, and other glomerular disorders. This mechanism-based potential suggests DMX-652 could serve a broader patient population beyond acute kidney injury.
Future clinical development programs may explore additional kidney disease indications following successful Phase 2 completion, subject to scientific and regulatory guidance. This multi-indication potential positions DMX-652 as a platform asset within Dimerix’s pipeline, offering significant long-term value creation opportunities.
Expert Endorsements Supporting DMX-652 Development
Dimerix has gained clinical validation for DMX-652 from leading kidney disease experts. Univ.-Prof. Dr. med. Alexander Zarbock, Chair and Director of Anesthesiology, Intensive Care Medicine, and Pain Therapy at University Hospital Münster, Germany, endorsed DMX-652 as a promising innovative solution for cardiac surgery-associated AKI.
Dr. Anker Lundemose, Executive Director of Mission Therapeutics Limited, highlighted DMX-652’s compelling Phase 1 clinical profile and the urgent need for novel AKI therapies. He praised Dimerix’s renal disease expertise and operational capabilities as ideal for advancing and commercializing DMX-652. Dr. Nina Webster, CEO and Managing Director of Dimerix, described DMX-652 as an exciting, differentiated compound that advances the company’s strategy to expand its renal pipeline.
